AUS
NZ
UK
CA
USA
IND
Highlights:
- Positive Trial Results and Stock Performance: Pfizer (NYSE:PFE) has gained nearly 22% since late April, driven by promising results from its gene therapy for hemophilia A and progress with an oral obesity drug.
- Attractive Dividend Yield: With a dividend yield of 5.46% and a strong track record of consistent growth, Pfizer offers a solid income stream for investors.
- Earnings Outlook and Valuation: Pfizer’s stock, trading at a forward P/E ratio of 12.91, is undervalued compared to the sector. Analysts expect a Q2 2024 EPS of $0.45 and revenue of $13.02 billion, with a positive consensus rating of "moderate buy."
Pfizer (NYSE:PFE), a prominent player in the pharmaceutical industry and a member of the S&P 500 Index ($SPX), is currently gaining attention from investors. After a period of underperformance post-COVID, Pfizer appears to be on the upswing.
The company recently announced encouraging results from a late-stage trial of its gene therapy for hemophilia A, adding to the excitement surrounding its progress with an oral obesity drug. These advancements have driven Pfizer's stock up nearly 22% from its lows in late April.
For income-focused investors, Pfizer's attractive 5.46% dividend yield stands out, supported by a decade-long track record of consistent dividend growth. As Pfizer gets ready to report earnings on Tuesday, July 30, here's a closer look at why this stock is generating interest.
Pfizer Stock Performance and Valuation
Pfizer, valued at $174 billion, operates in biopharma and business innovation, focusing on primary, specialty, and oncology care. Despite a significant revenue boost from COVID-19 products fading, Pfizer’s stock has rebounded from a challenging 2023, when it fell around 44%. Year-to-date, PFE has gained over 6%, though it may be overbought heading into the earnings report, suggesting potential short-term volatility.
Q1 2024 Earnings Review
In Q1 2024, Pfizer reported revenues of $14.9 billion, a 19% decline year-over-year, primarily due to reduced sales from Comirnaty and Paxlovid. Excluding these, revenues grew 11% operationally, reflecting the strength of Pfizer's core business. The company also achieved an adjusted diluted EPS of $0.82, with full-year revenue guidance maintained at $58.5 to $61.5 billion. Pfizer raised its adjusted diluted EPS forecast to $2.15-$2.35 and is targeting $4 billion in net cost savings by year-end.
Future Outlook
Analysts expect Pfizer to report an adjusted EPS of $0.45 and revenue of $13.02 billion in the upcoming report. With a forward P/E ratio of 12.91, Pfizer is trading at a 38% discount to the healthcare sector median of 21.04, and notably lower than its trailing P/E ratio of 21.67. The company’s consistent dividend payments and a robust pipeline, including recent approvals and breakthroughs, contribute to its investment appeal.
Pipeline Developments
Pfizer's recent successes include its gene therapy DURVEQTIX for severe hemophilia B and the FDA’s approval of TIVDAK for recurrent cervical cancer. These innovations, along with potential market entry in the GLP-1 space, could drive future growth and reinforce Pfizer's market position.
